AVR Stock Forecast & Price Target

Anteris Technologies Glb is viewed positively because DurAVR appears structurally differentiated from incumbent TAVR valves, with single-piece biomimetic design, low gradients in the low 8s in small annuli, and hemodynamics described as statistically indistinguishable from healthy controls, suggesting a real clinical and commercial edge. The PARADIGM trial adds credibility through being the first head-to-head TAVR study, while the company’s treatment of 130+ EFS/EMBARK patients, physician-led R&D, and Medtronic’s $90M strategic investment help de-risk execution and validate the platform. Financially, the company ended 2Q26 with $260.9M in cash and increased R&D 34% sequentially to $23.4M as U.S. enrollment began in May and France opened in June, supporting a strong runway for growth.

Anteris Technologies Glb is exposed to substantial fundamental risk because DurAVR still hinges on PARADIGM trial outcomes that could fall short of management and expectations, undermining the core investment case. The company also faces the possibility that the FDA takes longer than it is capitalized for to approve its PMA, a delay that would strain resources while it continues to incur significant operating losses and negative cash flow. In addition, DurAVR lacks a proven marketing or sales strategy, which could slow adoption by the medical community and increase the chance that expenses rise to an inoperable level before commercial traction is established.